Haleon Stock (NYSE:HLN)


ForecastOwnershipChartTranscripts

Previous Close

$9.25

52W Range

$8.65 - $11.28

50D Avg

$9.86

200D Avg

$9.84

Market Cap

$40.65B

Avg Vol (3M)

$10.18M

Beta

0.24

Div Yield

$0.12 (2.18%)

HLN Company Profile


Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

Yes

Country

GB

Employees

24,535

IPO Date

Jul 25, 2022

Website

HLN Performance


Latest Earnings Call Transcripts


Q2 26Jul 30, 26 | 10:00 AM
Q4 25Feb 25, 26 | 3:45 AM
Q3 25Oct 30, 25 | 5:15 AM

Peer Comparison


TickerCompany
CAHCardinal Health, Inc.
ALCAlcon Inc.
RMDResMed Inc.
HUMHumana Inc.
INSMInsmed Incorporated
BDXBecton, Dickinson and Company
ZTSZoetis Inc.
AAgilent Technologies, Inc.
IQVIQVIA Holdings Inc.
TAKTakeda Pharmaceutical Company Limited